Volume | 0 |
|
|||||
News | - | ||||||
Day High | Low High |
||||||
Day Low |
Company Name | Stock Ticker Symbol | Market | Type |
---|---|---|---|
VBI Vaccines Inc | VBIV | NASDAQ | Common Stock |
Open Price | Low Price | High Price | Close Price | Prev Close |
---|---|---|---|---|
0.59 |
Trades | Volume | Avg Volume | 52 Week Range |
---|---|---|---|
0 | 0 | - | 0.45 - 3.47 |
Last Trade Time | Type | Quantity | Stock Price | Currency |
---|---|---|---|---|
- | 0 | $ 0.59 | USD |
VBI Vaccines Inc Financials
Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
---|---|---|---|---|---|---|
13.98M | 23.69M | - | 8.68M | -93.84M | -3.96 | - |
Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
---|---|---|---|---|---|
- | - | - | - |
VBI Vaccines News
Loading Messages....
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical VBIV Price Data
Period | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
---|---|---|---|---|---|---|---|
1 Week | 0.63 | 0.658 | 0.58 | 0.6128433 | 177,914 | -0.04 | -6.35% |
1 Month | 0.61 | 1.35 | 0.55 | 0.6858407 | 1,144,582 | -0.02 | -3.28% |
3 Months | 0.72 | 1.35 | 0.53 | 0.6687882 | 472,310 | -0.13 | -18.06% |
6 Months | 0.48 | 1.35 | 0.45 | 0.6574083 | 282,901 | 0.11 | 22.92% |
1 Year | 2.87 | 3.47 | 0.45 | 1.66 | 506,808 | -2.28 | -79.44% |
3 Years | 88.80 | 129.30 | 0.45 | 55.14 | 1,578,894 | -88.21 | -99.34% |
5 Years | 60.00 | 217.20 | 0.45 | 74.60 | 3,525,825 | -59.41 | -99.02% |
VBI Vaccines Description
VBI Vaccines Inc is a US-based commercial-stage, the biopharmaceutical company which is engaged in developing next-generation vaccines to address unmet needs in infectious disease and immuno-oncology. The company manufactures Sci-B-Vac product which is a hepatitis B (HBV) vaccine for adults, children, and newborns. Its products include Virus-Like Particle which is vaccine platform which allows for the design of enveloped virus-like particle vaccines that closely mimic the target viruses. The company operates through the single segment being Developing vaccines to address unmet needs in infectious disease and immuno-oncology. |